EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:51137 - mianserin
| Formula | C18H20N2 |
| Net Charge | 0 |
| Average Mass | 264.372 |
| Monoisotopic Mass | 264.16265 |
| SMILES | CN1CCN2c3ccccc3Cc3ccccc3C2C1 |
| InChI | InChI=1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3 |
| InChIKey | UEQUQVLFIPOEMF-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | histamine agonist A drug that binds to and activates histamine receptors. Although they have been suggested for a variety of clinical applications, histamine agonists have so far been more widely used in research than therapeutically. alpha-adrenergic antagonist An agent that binds to but does not activate α-adrenergic receptors thereby blocking the actions of endogenous or exogenous α-adrenergic agonists. α-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. adrenergic uptake inhibitor Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. H1-receptor antagonist H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. serotonergic antagonist Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. EC 3.4.21.26 (prolyl oligopeptidase) inhibitor Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26). |
| Applications: | histamine agonist A drug that binds to and activates histamine receptors. Although they have been suggested for a variety of clinical applications, histamine agonists have so far been more widely used in research than therapeutically. alpha-adrenergic antagonist An agent that binds to but does not activate α-adrenergic receptors thereby blocking the actions of endogenous or exogenous α-adrenergic agonists. α-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. geroprotector Any compound that supports healthy aging, slows the biological aging process, or extends lifespan. adrenergic uptake inhibitor Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. sedative A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. H1-receptor antagonist H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. serotonergic antagonist Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. anxiolytic drug Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. antidepressant Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. antipsychotic agent Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| mianserin (CHEBI:51137) has role adrenergic uptake inhibitor (CHEBI:35640) |
| mianserin (CHEBI:51137) has role antidepressant (CHEBI:35469) |
| mianserin (CHEBI:51137) has role antipsychotic agent (CHEBI:35476) |
| mianserin (CHEBI:51137) has role anxiolytic drug (CHEBI:35474) |
| mianserin (CHEBI:51137) has role EC 3.4.21.26 (prolyl oligopeptidase) inhibitor (CHEBI:76779) |
| mianserin (CHEBI:51137) has role geroprotector (CHEBI:176497) |
| mianserin (CHEBI:51137) has role H1-receptor antagonist (CHEBI:37955) |
| mianserin (CHEBI:51137) has role histamine agonist (CHEBI:35678) |
| mianserin (CHEBI:51137) has role sedative (CHEBI:35717) |
| mianserin (CHEBI:51137) has role serotonergic antagonist (CHEBI:48279) |
| mianserin (CHEBI:51137) has role α-adrenergic antagonist (CHEBI:37890) |
| mianserin (CHEBI:51137) is a dibenzoazepine (CHEBI:47804) |
| Incoming Relation(s) |
| mianserin hydrochloride (CHEBI:31843) has part mianserin (CHEBI:51137) |
| IUPAC Name |
|---|
| 2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine |
| INNs | Source |
|---|---|
| mianserin | WHO MedNet |
| mianserina | WHO MedNet |
| miansérine | WHO MedNet |
| mianserinum | WHO MedNet |
| Synonyms | Source |
|---|---|
| 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine | ChemIDplus |
| J16.389I | ChEMBL |
| Tolvon | ChEMBL |
| Citations |
|---|